STAAHealthcare · Medical Instruments & SuppliesThe 11 Wall Street analysts covering STAAR Surgical Co. hold a median 12-month price target of $27 — +11.8% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 73 of 100 as at 26 Oct 2026 — in the upper half. Here, the model and the Street point the same way.
Consensus tells you what everyone already believes. The model scores STAAR Surgical Co. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Growth (98): Sales and profits are climbing, and climbing faster than before.
Accruals (37): A large share of reported profit has not shown up as cash, or the balance sheet is expanding quickly — both tend to unwind.
Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.
The bullish and bearish analyst opinions on STAA, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +11.8% from it.
Of the 20 most recent actions, 1 moved their price target up and 5 moved it down.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 29 Sept 2026 | Stifel | Upgrade | Buy | $28 → $31 |
| 22 Sept 2026 | Jefferies | Maintains | Buy | $28 → $23 |
| 17 Aug 2026 | Stifel | Maintains | Hold | — |
| 17 Aug 2026 | Stifel | Maintains | Hold | $31 → $28 |
| 13 Aug 2026 | Jefferies | Maintains | Buy | $29 → $28 |
| 13 Aug 2026 | Jefferies | Maintains | Buy | — |
| 13 Aug 2026 | UBS | Maintains | Sell | $20 → $19 |
| 13 Aug 2026 | UBS | Maintains | Sell | — |
| 13 Aug 2026 | Wedbush | Maintains | Outperform | — |
| 13 Aug 2026 | Wedbush | Maintains | Outperform | $40 → $37 |
| 4 Aug 2026 | Wedbush | Reiterates | Outperform | — |
| 4 Aug 2026 | Wedbush | Reiterates | Outperform | $40 |
| 28 July 2026 | UBS | Initiates | Sell | — |
| 28 July 2026 | UBS | Initiates | Sell | $20 |
| 22 July 2026 | Wedbush | Reiterates | Outperform | — |
| 22 July 2026 | Wedbush | Reiterates | Outperform | $40 |
| 16 July 2026 | Wedbush | Reiterates | Outperform | $40 |
| 16 July 2026 | Wedbush | Reiterates | Outperform | — |
| 29 May 2026 | Wedbush | Reiterates | Outperform | — |
| 15 May 2026 | Wells Fargo | Maintains | Equal-Weight | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
STAA appears in the Radar on the weeks it earns a place.
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 27 Oct 2026, STAAR Surgical Co. returned −13.0% against +13.5% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 2% of US stocks
Cheaper than 37% of US stocks
Cheaper than 31% of US stocks
Cheaper than 16% of US stocks
Higher than 93% of US stocks
Higher than 85% of US stocks
Higher than 87% of US stocks
Higher than 65% of US stocks
Higher than 50% of US stocks
Higher than 45% of US stocks
Higher than 80% of US stocks
Higher than 1% of US dividend payers
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
STAAR Surgical Co. has a market value of $1.1B and an enterprise value of $938.1M.
Revenue in the twelve months to 30 June 2026: $339.6M. The latest quarter grew 111.0% year on year.
Net income over the same four quarters: $3.8M, a 1.1% net margin.
Diluted earnings per share, trailing twelve months: $0.07.
Free cash flow in the twelve months to 30 June 2026: −$6.7M.
STAAR Surgical Co. spent $6.8M on share buybacks in the twelve months to 30 June 2026.
Trailing P/E: 270.1×; forward P/E: 19.4× — the forward figure prices analyst consensus estimates, not reported earnings.
Forward dividend yield: 0.00%, paying out 0% of earnings.
STAAR Surgical Co. employs 921 people — $369K of revenue per employee.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own STAAR Surgical Co. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
STAAR Surgical announced that CEO Warren Foust and CFO Deborah Andrews will participate in two investor conferences in November. The excerpt lists the Stifel 2026 Healthcare Conference on November 10 in New York.
Why it matters — The conferences provide occasions for company leadership to engage with investors.
Levi & Korsinsky announced an investigation into possible breaches of fiduciary duties by certain officers and directors of STAAR Surgical Company.
Why it matters — The investigation concerns the conduct of STAAR Surgical’s officers and directors and may be relevant to shareholders following the company.
STAAR Surgical will release its third-quarter 2026 financial results and shareholder letter after market close on November 4, then host an earnings call and webcast at 5:30 p.m. ET.
Why it matters — STAA watchers can follow the scheduled release and call for the company’s quarterly results and related discussion.
STAAR Surgical appointed Andrew Pilon, O.D., as Vice President of Business Development. He will report to CEO Warren Foust and work with the senior leadership team on business development opportunities.
Why it matters — The appointment adds a business development executive who will work with STAAR’s senior leadership team.
STAAR Surgical's stock rose nearly 8% on Tuesday after a stock commentator expressed a bullish view, citing positive sales momentum, particularly in a key overseas market. The analyst reportedly now considers the stock a buy.
Why it matters — A STAA watcher would care because a prominent pundit upgrading its outlook and highlighting overseas sales strength could signal growing investor confidence in the company's growth trajectory.
The 11 Wall Street analysts covering STAAR Surgical Co. have a median 12-month price target of $27, with estimates ranging from $19 to $37. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 11 analysts covering STAAR Surgical Co., 4 rate it a Buy, 6 a Hold and 1 a Sell. Ticker Nerd's systematic factor model ranks STAAR Surgical Co. 73 out of 100 across roughly 4,600 US stocks as at 26 Oct 2026. None of this is personal advice — it does not consider your circumstances.
As at 26 Oct 2026, STAAR Surgical Co. ranks 73 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Growth (98 of 100).
No one can know that. What the data says: the median 12-month target from 11 analysts implies +11.8% from the last close, and Ticker Nerd's factor model ranks STAAR Surgical Co. 73 out of 100 as at 26 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering STAAR Surgical Co. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for STAA are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $19 to $37 over the next 12 months.
STAAR Surgical Co. returned -13.0% over the 12 months to 27 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.
STAAR Surgical Company is a medical technology company that designs, develops, manufactures, and markets implantable lenses for the eye and companion delivery systems. Its core product line includes Implantable Collamer® Lenses used in refractive surgery to address visual disorders such as myopia, hyperopia, astigmatism, and presbyopia.
The most recent item we track (Business Wire, 27 Oct 2026): "STAAR Surgical to Participate in Upcoming Investor Conferences". STAAR Surgical announced that CEO Warren Foust and CFO Deborah Andrews will participate in two investor conferences in November. The excerpt lists the Stifel 2026 Healthcare Conference on November 10 in New York.
STAAR Surgical Company is a medical technology company that designs, develops, manufactures, and markets implantable lenses for the eye and companion delivery systems. Its core product line includes Implantable Collamer® Lenses used in refractive surgery to address visual disorders such as myopia, hyperopia, astigmatism, and presbyopia. The company focuses on ophthalmic surgery solutions that are used by eye care professionals seeking lens-based vision correction options. STAAR Surgical also offers accessory systems that support lens implantation procedures and help deliver its products into the eye. Headquartered in Lake Forest, California, and founded in 1982, STAAR Surgical serves a global market centered on eye care and vision correction, with a business model built around specialized surgical devices and related procedure support.
CEO Mr. Warren Foust · 921 employees · United States · https://www.staar.com
